Education
About Us
Working with TipRanks
Follow Us
Numinus Wellness (TSE:NUMI)
TSX:NUMI
Top Page
Numinus Wellness
(TSX:NUMI)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.00
▼(-100.00% Downside)
Action:ReiteratedDate:08/20/25
The overall stock score for Numinus Wellness is primarily impacted by its poor financial performance, characterized by declining revenues and high operating losses. The technical analysis indicates a neutral position with no clear trend, while the valuation is unattractive due to a negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall score, highlighting significant challenges for the company.
Positive Factors
Innovative Business Model
Numinus's focus on psychedelic-assisted therapies positions it as a leader in an emerging field, potentially capturing a growing market in mental health solutions.
Diverse Revenue Streams
Multiple revenue streams from clinical services, research, and training provide resilience against market fluctuations and enhance long-term financial stability.
Strategic Partnerships
Collaborations with academic and mental health institutions enhance research capabilities and market reach, bolstering long-term growth potential and innovation.
Negative Factors
Revenue Decline
A steep decline in revenue growth indicates challenges in market penetration and product adoption, threatening long-term sustainability and competitive position.
High Operating Losses
Substantial operating losses undermine profitability, limiting the company's ability to reinvest in growth initiatives and posing a risk to financial health.
High Leverage
Significant leverage increases financial risk, potentially constraining cash flow and reducing flexibility in strategic decision-making, impacting long-term viability.
Numinus Wellness (NUMI) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$13.86M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees200
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)N/A
Shares Outstanding320,551,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)14.24
Price to Sales (P/S)2.48
P/FCF Ratio-0.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Numinus Wellness Business Overview & Revenue Model
Company DescriptionNuminus Wellness Inc. provides solutions to develop and deliver psychedelic-assisted psychotherapy and transform the mental health landscape. The company operates in two divisions, Salvation Botanicals and Numinus Health. The Salvation Botanicals division offers laboratory services, such as cultivation, analytical testing, product research and development, and ancillary services in the area of psychedelics; and full suite testing and custom testing of cannabis. The Numinus Health division provides supportive therapies and technologies to heal, connect, and grow with a focus on treating mental health and substance abuse; and services for psychotherapy, counselling, neurofeedback, physiotherapy, and other therapies. This division also offers training, facilities, and other operational resources to practitioners. The company is headquartered in Vancouver, Canada.
How the Company Makes MoneyNuminus Wellness generates revenue through multiple streams, primarily from its clinical services, research initiatives, and partnerships. The company earns income by providing therapeutic treatment programs that utilize psychedelic substances, alongside conducting clinical trials which may be funded by partnerships with pharmaceutical companies and research institutions. Additionally, Numinus offers training programs for healthcare professionals in psychedelic therapy, creating another revenue stream. Significant partnerships with academic institutions and other entities in the mental health and wellness space also contribute to its earnings, enabling the company to leverage external funding and collaborative opportunities.
Numinus Wellness Earnings Call Summary
Earnings Call Date:Jul 11, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Apr 09, 2026
Earnings Call Sentiment Neutral
The call highlighted significant strategic initiatives, including cost reductions and a major acquisition aimed at future growth. However, these positives were offset by declining revenue and margins, leading to a balanced sentiment.Q3-2024 Updates
Positive Updates
Significant Cost Reduction Achieved
The company reduced its headcount by 60% and successfully lowered its burn rate to under $1 million per month, maintaining this target into the third quarter.
Strategic Transition to U.S. Operations
Numinus transitioned out of Canadian clinic operations, focusing on U.S.-based clinics. New client appointments increased by 24% and ketamine and SPRAVATO appointments rose by 15% in Q3.
Proposed Acquisition of MedBright AI
The acquisition of MedBright AI aims to enhance clinic efficiency with AI solutions, providing infrastructure in a SaaS model, and is seen as a significant opportunity for growth.
Increased Revenue from Cedar Clinical Research
Revenue from Cedar Clinical Research increased by 10.7% to $0.8 million in Q3 due to a new clinical trial, showing a positive trend despite other declines.
Growth in Practitioner Training Program
The program grew from 400 learners in Q4 2023 to over 1,650 by May 31, 2024, indicating strong interest and uptake.
Negative Updates
Decrease in Overall Revenue
Quarterly revenue declined by 1.9% from Q2 2024 and 17.3% year-over-year, primarily due to the closure of the Arizona clinic and transitioning services.
Decline in Gross Margins
Gross margins fell to 22% in Q3 from 24% in Q2 and 34.5% in Q3 2023, reflecting challenges in maintaining profitability.
Net Loss from Continuing Operations
Reported a net loss of $5.1 million for the quarter, indicating ongoing financial challenges despite cost-cutting measures.
Company Guidance
During the Numinus Wellness Inc. Q3 2024 earnings call, the company provided comprehensive guidance focused on optimizing operations for profitability and strategic growth. Key initiatives included the closure of non-revenue-generating business lines and a significant reduction in headcount by 60%, with an aim to cut the burn rate to under $1 million per month, which was achieved by October. The company also transitioned out of Canadian clinic operations, partnering with Field Trip Health, and concentrated on U.S. clinic operations, where appointments decreased by 6% over Q2, but new client appointments rose by 24%, and ketamine and SPRAVATO appointments increased by 15%. Revenue for the quarter was $4.3 million, reflecting a year-over-year decline due to the wind-down of Arizona clinics and a focus on high-margin services. Operating expenditures decreased by 22% to $4.9 million, with a net loss of $5.1 million or $0.02 per share. Looking forward, Numinus is set to acquire MedBright AI, enhancing its capabilities with AI-driven solutions and rebranding to Numinus Intelligence. The acquisition is expected to close by August, poised to open new high-margin revenue streams in the U.S. mental health sector.Numinus Wellness Financial Statement Overview
Summary
Numinus Wellness is facing significant financial challenges, with declining revenues, high operating losses, and substantial leverage. The company needs to address its cash flow issues and improve profitability to enhance financial stability. The current financial position suggests a need for strategic adjustments to achieve sustainable growth.Income Statement
Numinus Wellness has experienced significant revenue decline with a negative growth rate of -80.55% in the latest period. The company is facing substantial losses, as indicated by a negative net profit margin of -471.23% and negative EBIT and EBITDA margins. Despite a positive gross profit margin of 27.97%, the overall profitability is severely impacted by high operating losses.30
Negative
Balance Sheet
The company's balance sheet shows a high debt-to-equity ratio of 2.80, indicating significant leverage and potential financial risk. Return on equity is negative at -27.08%, reflecting poor profitability relative to shareholder's equity. The equity ratio is low, suggesting limited equity financing relative to total assets.40
Negative
Cash Flow
Operating cash flow and free cash flow are both negative, indicating cash outflows from operations. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow is somewhat aligned with net income, albeit both are negative. The company has shown some improvement in free cash flow growth, but overall cash flow health remains weak.35
Negative
| Breakdown | May 2025 | Aug 2023 | Aug 2022 | Nov 2021 | Nov 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.17M | 3.75M | 6.49M | 1.51M | 881.18K |
| Gross Profit | 1.17M | 8.37M | 1.78M | -81.54K | 88.05K |
| EBITDA | -13.94M | -26.66M | -42.85M | -17.94M | -8.85M |
| Net Income | -19.64M | -30.26M | -44.88M | -18.77M | -9.60M |
Balance Sheet | |||||
| Total Assets | 10.77M | 24.33M | 52.63M | 64.14M | 5.12M |
| Cash, Cash Equivalents and Short-Term Investments | 1.96M | 8.58M | 33.04M | 59.29M | 1.63M |
| Total Debt | 2.03M | 7.20M | 7.85M | 1.60M | 421.63K |
| Total Liabilities | 10.05M | 10.28M | 11.42M | 3.31M | 2.32M |
| Stockholders Equity | 725.43K | 14.05M | 41.21M | 60.83M | 2.80M |
Cash Flow | |||||
| Free Cash Flow | -17.50M | -23.14M | -27.48M | -16.22M | -5.39M |
| Operating Cash Flow | -17.48M | -22.76M | -26.23M | -15.58M | -5.36M |
| Investing Cash Flow | 860.08K | -369.57K | 123.19K | -739.25K | -128.69K |
| Financing Cash Flow | 4.54M | -1.46M | 7.34K | 73.98M | 7.02M |
Numinus Wellness Technical Analysis
Negative
0.04
Price Trends
0.04
Negative
0.04
Negative
0.04
Negative
Market Momentum
>-0.01
Neutral
100.00
Negative
0.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NUMI, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NUMI.
Numinus Wellness Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | C$235.26M | 9.17 | 28.24% | 1.03% | 0.19% | ― | |
63 Neutral | C$28.81M | -92.15 | 4.10% | ― | 19.61% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | C$1.11M | -0.14 | 202.02% | ― | -22.61% | 7.72% | |
41 Neutral | C$13.86M | -5.16 | ― | ― | ― | ― | |
39 Underperform | C$413.49K | -0.87 | ― | ― | ― | ― |
* Healthcare Sector Average
TSE:NUMI
Numinus Wellness
0.04
0.00
0.00%
TSE:CRRX
CareRx
3.75
1.02
37.36%
TSE:NLH
Nova Leap Health
0.33
0.09
37.50%
TSE:JNH
Jack Nathan Medical
0.01
>-0.01
-33.33%
TSE:PHA
Premier Health of America Inc
0.02
-0.04
-66.67%
TSE:CALM
Revitalist Lifestyle & Wellness Ltd
0.02
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.